The Siesta Group

Executive Summary

The Siesta Group is a specialized service provider for measuring electrophysiological and activity-related signals in clinical trials, with a focus on EEG, sleep, and actigraphy. Founded in 2002 in Vienna, Austria, the company offers end-to-end services including consulting, site feasibility, site training, central data analysis, and device rental. As a seasoned player in the neuroscience and digital health space, The Siesta Group supports pharmaceutical and biotech sponsors in generating high-quality biomarker data for CNS trials, where reliable central nervous system measurements are critical. Despite being categorized as pre-clinical, the company's 24-year track record and established operational infrastructure position it as a reliable partner for clinical-stage studies, bridging the gap between novel neuroscience targets and validated endpoint measurement. The growing demand for objective, digital biomarkers in CNS drug development—particularly in indications like Alzheimer's, sleep disorders, and depression—presents a significant market opportunity. The Siesta Group's comprehensive service model and deep expertise in EEG and actigraphy enable sponsors to reduce trial risk and accelerate timelines. By standardizing data collection and analysis across sites, the company helps improve signal detection and regulatory acceptance. With increasing investment in digital health and decentralized trials, The Siesta Group is well-positioned to expand its client base and capitalize on the shift toward more quantitative, real-world evidence in neurology.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership for Alzheimer's EEG Biomarker Trial60% success
• Q4 2026Expansion into Actigraphy-Based Sleep Apnea Diagnostic Services50% success
• 2027FDA Acceptance of EEG Endpoint Based on Company Methodology40% success